Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin
Status:
Completed
Trial end date:
2017-01-13
Target enrollment:
Participant gender:
Summary
This is an open-label Phase I study of plasma, genitourinary, rectal, and pharyngeal
pharmacokinetics of a single 1000mg oral dose of solithromycin. Study Objectives: The primary
objective is to determine the pharmacokinetics of solithromycin in plasma, vaginal, cervical,
seminal, rectal, and pharyngeal fluid samples after a single 1000mg oral dose.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)